Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiang Xing

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Current Opinion in Molecular Therapeutics|November 7, 2003
Technology evaluation: R-1549, Antisoma/RochePei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
MDX-060. MedarexXiu Feng Hu, Pei Xiang Xing
Expert Opinion on Therapeutic Targets|June 7, 2005
Cripto as a target for cancer immunotherapyXiu Feng Hu, Pei Xiang Xing
Molecules (Basel, Switzerland)|July 27, 2022
Preliminary Study on Phytochemical Constituents and Biological Activities of Essential Oil from <i>Myriactis nepalensis</i> LessJikai Fu, Yang Gao, Xiang Xing
Drug News & Perspectives|September 30, 2005
Cripto monoclonal antibodiesXiu Feng Hu, Pei Xiang Xing
Current Opinion in Molecular Therapeutics|February 6, 2004
Discovery and validation of new molecular targets for ovarian cancerXiu Feng Hu, Pei Xiang Xing
BMC Bioinformatics|January 23, 2013
Predicting PDZ domain mediated protein interactions from structureShirley Hui, Xiang Xing, Gary D Bader
Chemistry & Biodiversity|May 8, 2020
Analysis of Chemical Composition and Assessment of Antioxidant, Cytotoxic and Synergistic Antibacterial Activities of Essential Oils from Different Plant Parts of Piper boehmeriifoliumRuo-Lan Wang, Yang Gao, Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
CNTO-328 (Centocor)Jie Li, Xiu Feng Hu, Pei Xiang Xing
Cellular Immunology|October 7, 2011
Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survivalJie Li, Bruce Edward Loveland, Pei Xiang Xing
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Current Opinion in Molecular Therapeutics|November 7, 2003
Technology evaluation: R-1549, Antisoma/RochePei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
MDX-060. MedarexXiu Feng Hu, Pei Xiang Xing
Expert Opinion on Therapeutic Targets|June 7, 2005
Cripto as a target for cancer immunotherapyXiu Feng Hu, Pei Xiang Xing
Molecules (Basel, Switzerland)|July 27, 2022
Preliminary Study on Phytochemical Constituents and Biological Activities of Essential Oil from <i>Myriactis nepalensis</i> LessJikai Fu, Yang Gao, Xiang Xing
Drug News & Perspectives|September 30, 2005
Cripto monoclonal antibodiesXiu Feng Hu, Pei Xiang Xing
Current Opinion in Molecular Therapeutics|February 6, 2004
Discovery and validation of new molecular targets for ovarian cancerXiu Feng Hu, Pei Xiang Xing
BMC Bioinformatics|January 23, 2013
Predicting PDZ domain mediated protein interactions from structureShirley Hui, Xiang Xing, Gary D Bader
Chemistry & Biodiversity|May 8, 2020
Analysis of Chemical Composition and Assessment of Antioxidant, Cytotoxic and Synergistic Antibacterial Activities of Essential Oils from Different Plant Parts of Piper boehmeriifoliumRuo-Lan Wang, Yang Gao, Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
CNTO-328 (Centocor)Jie Li, Xiu Feng Hu, Pei Xiang Xing
Cellular Immunology|October 7, 2011
Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survivalJie Li, Bruce Edward Loveland, Pei Xiang Xing
Pageof 13